SEARCH

SEARCH BY CITATION

References

  • 1
    Wattanakit K, Cushman M. Chronic kidney disease and venous thormboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 2009; 15: 40812.
  • 2
    Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 4207.
  • 3
    Iprivask [package insert]. Hunt Valley, MD: Canyon Pharmaceuticals, Inc; 2009.
  • 4
    Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P, Close P. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997; 79: 32633.
  • 5
    Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 132935.
  • 6
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 7
    Crowe E, Halpin D, Stevens P, on behalf of the Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: 81215.
  • 8
    Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003; 41: 205.
  • 9
    Snapinn SM. Interpreting interaction: the classical approach. Drug Inf J 1998; 32: 4338.
  • 10
    Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR and Folson AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 13540.
  • 11
    Shilpak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevation of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 8792.
  • 12
    Vaziri ND, Paule P, Toohey J, Hung E, Alikhani S, Darwish R, Pahl MV. Acquired deficiency and urinary excretion of antithrombin III in nephritic syndrome. Arch Intern Med 1984; 144: 18023.
  • 13
    Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 203847.
  • 14
    Lefevre G, Duval M, Gauron S, Brookman LJ, Rolan PE, Morris TM, Piraino AJ, Morgan JM, Palmisano M, Close P. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997; 62: 509.
  • 15
    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight-heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 67384.